European Medicines Agency Endorses Alvotech’s AVT03 Biosimilar

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for AVT03, a proposed biosimilar from Alvotech. This decision, announced on September 22, 2025, marks a significant step forward for the biotechnology company, which specializes in developing biosimilar medicines aimed at improving patient access to essential treatments.

AVT03 is designed to be a biosimilar to Prolia® (denosumab 60 mg/mL single-use pre-filled syringe) and Xgeva® (denosumab 70 mg/mL single-use vial). With this positive opinion, Alvotech is set to collaborate with its commercial partners, STADA Arzneimittel AG and Dr. Reddy’s Laboratories SA, to bring this important treatment to market in Europe, including Switzerland and the UK, where each partner holds semi-exclusive commercial rights.

In a statement, Joseph McClellan, Chief Scientific and Technical Officer of Alvotech, expressed enthusiasm about the approval process: “We look forward to working with our partners in making denosumab available more widely to patients and caregivers. This important step demonstrates how Alvotech’s specialization in biosimilars development and manufacture and integrated end-to-end platform enables broader access to affordable biologic medicines.”

The approval of AVT03 is expected to enhance competition in the market for denosumab, a critical medication used in the treatment of osteoporosis and certain cancers. By introducing a biosimilar option, Alvotech aims to provide a more cost-effective alternative for patients, ultimately improving treatment accessibility in Europe.

This recommendation from the EMA is a crucial milestone in the regulatory process. The next steps will involve a thorough review before the final marketing authorization is granted. If approved, AVT03 could soon be available to patients, potentially transforming treatment options for those in need.

Alvotech’s commitment to biosimilar development is part of a broader effort within the pharmaceutical industry to increase the availability of biologic treatments. As healthcare systems around the world continue to seek ways to manage costs while ensuring patient access to necessary medications, the introduction of biosimilar products like AVT03 may play a pivotal role.

With the EMA’s endorsement, Alvotech is poised to make a significant impact in the biosimilars market, offering hope to patients who require effective and affordable treatment options.